Brief: Mendus: Data From Advance II Phase 2 Trial Demonstrate Durable Survival Of AML Patients Treated With Vididencel

Mendus AB (publ)

09/12/2024 07:01

Dec 9 (Reuters) - Mendus AB (publ)  IMMUN.ST :
    * UPDATED DATA FROM THE ADVANCE II PHASE 2 TRIAL PRESENTED
AT ASH
DEMONSTRATE DURABLE SURVIVAL OF AML PATIENTS TREATED WITH
VIDIDENCEL
    * MEDIAN RELAPSE-FREE AND OVERALL SURVIVALL MEDIAN HAS NOT
BEEN
REACHED
    * ESTIMATED 5-YEAR SURVIVAL STANDS AT 58%
    * IMMUNOMONITORING DATA CONFIRM THAT VIDIDENCEL ACTS AS AN
ACTIVE
IMMUNOTHERAPY IN AML
    * DATA SHOW 13 OUT OF 20 PATIENTS TREATED WITH VIDIDENCEL
WERE
ALIVE, 11 PATIENTS WERE IN CR1 AS OF NOV 4, CUT-OFF-DATE, WITH
MEDIAN FOLLOW-UP OF 41.8 MTHS

Source text:  ID:nMFN6kF5RV 
Further company coverage:  IMMUN.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))